


We claim:

1. The compound of formula I and the pharmaceutically acceptable salts and tautomers thereof:

5



wherein:

$R^1$  is  $-C_{1-6}$ alkyl;

$R^2$  is -phenyl, unsubstituted, mono- or polysubstituted with a substituent selected from the group consisting of -halo,  $-C_{1-6}$ alkyl,  $-CF_3$ ,  $-O-C_{1-6}$ alkyl, and  $-NO_2$ ;

$R^3$  is selected from the group consisting of -H and  $-C_{1-6}$ alkyl;

$R^4$  is  $-C_{1-6}$ alkyl;

$R^5$  is  $-C_{1-6}$ alkyl;

$R^6$  is each independently selected from the group consisting of: -halo,  $-C_{1-6}$ alkyl,  $-CF_3$ ,  $-O-C_{1-6}$ alkyl, and  $-NO_2$ ; and

$q$  is an integer from 0 to 4.

2. The compound of claim 1 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^1$  is -methyl.

3. The compound of claim 2 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^2$  is -phenyl, unsubstituted, mono- or polysubstituted with a substituent selected from the group consisting of: -halo,  $-C_{1-6}$ alkyl,  $-CF_3$ , and  $-O-C_{1-6}$ alkyl.

25

4. The compound of claim 3 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^2$  is selected from the group consisting of: -3-chlorophenyl, -4-chlorophenyl, -4-methoxyphenyl, -3-trifluoromethyl-phenyl, -4-trifluoromethyl-phenyl, -

- 3,4-dichlorophenyl, -3-bromophenyl, -4-bromophenyl and -3-trifluoromethyl-4-chlorophenyl.
5. The compound of claim 3 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^3$  is -H.
6. The compound of claim 4 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^3$  is -H.
7. The compound of claim 5 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^4$  is  $-CH_3$ .
8. The compound of claim 6 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^4$  is  $-CH_3$ .
9. The compound of claim 7 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^5$  is  $-CH_3$ .
10. The compound of claim 8 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^5$  is  $-CH_3$ .
11. The compound of claim 9 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^6$  is selected from the group consisting of  $-CH_3$  and -halo.
12. The compound of claim 10 and the pharmaceutically acceptable salts and tautomers thereof, wherein  $R^6$  is selected from the group consisting of  $-CH_3$  and -halo.
13. The compound of claim 11 and the pharmaceutically acceptable salts and tautomers thereof, wherein q is 0 to 2.

14. The compound of claim 12 and the pharmaceutically acceptable salts and tautomers thereof, wherein q is 0 to 2.


15. The compound of claim 1, wherein said compound is selected from the group

5 consisting of:

- (1) Methyl-{1-[2-(1-phenyl-ethyl)-phenyl]-ethyl}-amine,
- (2) Methyl-{1-[2-(1-phenyl-propyl)-phenyl]-ethyl}-amine,
- (3) Dimethyl-{1-[2-(1-phenyl-ethyl)-phenyl]-ethyl}-amine,
- (4) Methyl-{1-[2-(1-phenyl-ethyl)-phenyl]-propyl}-amine,
- 10 (5) (1-{2-[1-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (6) {1-[4,5-Dimethyl-2-(1-phenyl-ethyl)-phenyl]-ethyl}-methyl-amine,
- (7) {1-[4,5-Dichloro-2-(1-phenyl-ethyl)-phenyl]-ethyl}-methyl-amine,
- (8) (1-{2-[1-(4-Chloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (9) (1-{2-[1-(3-Chloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- 15 (10) (1-{2-[1-(4-Methoxy-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (11) Methyl-(1-{2-[1-(4-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-amine,
- (12) Methyl-(1-{2-[1-(3-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-amine,
- (13) (1-{2-[1-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- (14) (1-{2-[1-(4-Bromo-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
- 20 (15) (1-{2-[1-(3-Bromo-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine, and
- (16) (1-{2-[1-(4-Bromo-3-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-methyl  
amine,

and pharmaceutically acceptable salts and tautomers thereof.

- 25 16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient the compound of formula I and pharmaceutically acceptable salts and tautomers thereof:



wherein:

$R^1$  is  $-C_{1-6}$ alkyl;

$R^2$  is -phenyl, unsubstituted, mono- or polysubstituted with a substituent  
 5 selected from the group consisting of -halo,  $-C_{1-6}$ alkyl,  $-CF_3$ ,  $-O-C_{1-6}$ alkyl, and  
 $-NO_2$ ;

$R^3$  is selected from the group consisting of -H and  $-C_{1-6}$ alkyl;

$R^4$  is  $-C_{1-6}$ alkyl;

$R^5$  is  $-C_{1-6}$ alkyl;

$R^6$  is each independently selected from the group consisting of: -halo,  
 10  $-C_{1-6}$ alkyl,  $-CF_3$ ,  $-O-C_{1-6}$ alkyl, and  $-NO_2$ ; and

$q$  is an integer from 0 to 4.

17. A method of treating depression in a patient, which method comprises administering  
 15 to a patient a therapeutically effective amount of the compound of claim 1.

18. The method of claim 17, wherein said depression is selected from the group  
 consisting of: unipolar depression, dysthymia, bipolar depression, treatment-resistant  
 depression, and depression in the medically-ill.